Related Experiment Videos
Abstract:
ICR mice were challenged with conidia of Aspergillus fumigatus given either intranasally or intravenously, and treated beginning 1 day later with itraconazole, amphotericin B, or the vehicles for these two agents. Mice challenged intravenously and treated with either antifungal drug had prolonged survival over controls, and had lower tissue counts in the kidneys than the controls. However, mice challenged intranasally had neither prolonged survival nor lower lung tissue counts than the controls.
Insights
Antifungal drugs itraconazole and amphotericin B prolonged survival in mice with intravenous Aspergillus fumigatus infections. However, these antifungal treatments did not improve survival for intranasal infections.
Area of Science:
- Mycology
- Infectious Diseases
- Pharmacology
Background:
- Aspergillus fumigatus is a common mold that can cause serious infections, particularly in immunocompromised individuals.
- Antifungal medications are crucial for treating invasive aspergillosis, but their efficacy can vary depending on the route of infection.
- Investigating the effectiveness of antifungal drugs against different routes of fungal challenge is essential for optimizing treatment strategies.
Purpose of the Study:
- To evaluate the efficacy of itraconazole and amphotericin B in treating Aspergillus fumigatus infections in mice.
- To compare the effectiveness of these antifungal agents when administered via different routes of infection (intranasal vs. intravenous).
Main Methods:
- ICR mice were experimentally infected with Aspergillus fumigatus conidia.
- Infection was established through either intranasal or intravenous administration of the fungus.
- Mice received treatment with itraconazole, amphotericin B, or placebo vehicles starting one day post-infection.
Main Results:
- Intravenous infection with Aspergillus fumigatus led to prolonged survival in mice treated with either itraconazole or amphotericin B compared to controls.
- Mice with intravenous infections treated with antifungals showed reduced fungal tissue burden in the kidneys.
- Intranasal infection with Aspergillus fumigatus did not result in prolonged survival or reduced lung fungal burden in mice treated with either antifungal drug.
Conclusions:
- Itolraconazole and amphotericin B demonstrate efficacy in treating systemic (intravenous) Aspergillus fumigatus infections in a murine model.
- These antifungal agents were not effective in improving survival or reducing fungal burden in a murine model of intranasal Aspergillus fumigatus infection.
- The route of Aspergillus fumigatus infection significantly impacts the therapeutic response to standard antifungal treatments like itraconazole and amphotericin B.